Kersten Dirk 4
4 · Dyne Therapeutics, Inc. · Filed Jun 9, 2026
Research Summary
AI-generated summary of this filing
Dyne Therapeutics Director Dirk Kersten Receives Option Grant
What Happened
Dirk Kersten, a director of Dyne Therapeutics (DYN), received a derivative award on 2026-06-05: an option covering 35,152 shares reported at $0.00. This is an equity grant (not an open‑market purchase or sale) and represents the right to acquire shares subject to vesting and other terms.
Key Details
- Transaction date: June 5, 2026; Form 4 filed June 9, 2026 (accession 0001193125-26-264021).
- Instrument: Option/derivative covering 35,152 shares; reported acquisition price $0.00.
- Vesting: The option vests in full on the earlier of (i) June 5, 2027 or (ii) the issuer’s 2027 Annual Meeting of Stockholders, subject to continued service (footnote).
- Shares owned after the transaction: not specified in the provided filing details.
- No sale or immediate exercise was reported in this filing.
Context
This is a compensation/retention award to a director rather than a purchase or sale — common practice to align directors with shareholder interests. Because it’s a time‑based option grant, it does not represent immediate buying or selling of stock; the economic impact depends on future vesting and any exercise price or sale decisions.
Insider Transaction Report
- Award
Stock option (right to buy)
[F1]2026-06-05+35,152→ 35,152 totalExercise: $17.04Exp: 2036-06-04→ Common Stock (35,152 underlying)
Footnotes (1)
- [F1]This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.